What is the LIBRA 3.0 HRD Program?
Oncode and AstraZeneca have established a partnership to enhance access to Homologous Recombination
Deficiency (HRD) testing through the Libra 3.0 HRD Program for newly-diagnosed advanced ovarian cancer, fallopian tube, or primary peritoneal cancer patients. The program is dedicated to ensuring that patients receive timely and accurate
HRD testing as part of their diagnostic journey to improve overall patient outcomes.
Oncode and AstraZeneca have established a partnership to enhance access to Homologous Recombination Deficiency (HRD) testing through the Libra 3.0 HRD Program for newly-diagnosed advanced ovarian cancer, fallopian tube, or primary peritoneal cancer patients. The program is dedicated to ensuring that patients receive timely and accurate HRD testing as part of their diagnostic journey to improve overall patient outcomes.
Importance of assessing genomic instability
There exist a subset of patients who are HRD-positive but lack a BRCA1/2 mutation. Genomic instability scores are used to discern this subset of patients who would also benefit from PARP inhibitors.
Test Description
FFPE tissue NGS test panel examining two different types of biomarkers:
Assessment of genetic mutations. (in BRCA1 and BRCA2 genes)
Assessment of genomic instability. (LOH, LST, TAI markers)
- LOH: Loss of heterozygosity.
- LST: Large-scale state transitions.
- TAI: Telomeric-allelic imbalance.
Eligibility Criteria
Adult patients with newly diagnosed advanced epithelial ovarian with non-mucinous histology (e.g., High-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma and low-grade serous carcinoma), fallopian tube, or primary peritoneal cancer.
If you have any questions or would like to learn more about the LIBRA 3.0 HRD Program, please do not hesitate to contact us.
MY-13506_FEB2024